{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:12:37Z","timestamp":1791054757512,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/pas.0b013e3182759008","type":"journal-article","created":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T11:38:42Z","timestamp":1361014722000},"page":"563-570","source":"Crossref","is-referenced-by-count":21,"title":["Follow-up Data of 10 Patients With B-cell Non-Hodgkin Lymphoma With a CD20-negative Phenotypic Change After Rituximab-containing Therapy"],"prefix":"10.1097","volume":"37","author":[{"given":"Akiko M.","family":"Maeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab)(2) is sufficient for induction of apoptosis in B-cell lines.","volume":"51","author":"Cardarelli","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkins lymphoma.","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/A:1008265313133","article-title":"Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.","volume":"9","author":"Tobinai","year":"1998","journal-title":"Ann Oncol"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1056\/NEJM198506273122602","article-title":"Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.","volume":"312","author":"Meeker","year":"1985","journal-title":"N Engl J Med"},{"key":"R10-11-20210131","first-page":"3916","article-title":"CD20-negative relapse in B-cell lymphoma after treatment with rituximab.","volume":"16","author":"Kinoshita","year":"1998","journal-title":"J Clin Oncol"},{"key":"R11-11-20210131","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.","volume":"5","author":"Davis","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2141.1999.01608.x","article-title":"Clonal selection of CD20-negative non-Hodgkins lymphoma cells after treatment with anti-CD20 antibody rituximab.","volume":"106","author":"Schmitz","year":"1999","journal-title":"Br J Haematol"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","article-title":"Loss of CD20 expression following treatment with rituximab (chimeric monoclonal anti-CD20): a retrospective cohort analysis.","volume":"114","author":"Foran","year":"2001","journal-title":"Br J Haematol"},{"key":"R14-11-20210131","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/1042819021000040044","article-title":"Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.","volume":"43","author":"Chu","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","article-title":"Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkins lymphoma: a retrospective review.","volume":"119","author":"Kennedy","year":"2002","journal-title":"Br J Haematol"},{"key":"R16-11-20210131","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/039463200601900218","article-title":"Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.","volume":"19","author":"Goteri","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.pai.0000145130.02931.74","article-title":"Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.","volume":"14","author":"Seliem","year":"2006","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00277-003-0694-1","article-title":"CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.","volume":"82","author":"Alovaro-Naranjo","year":"2003","journal-title":"Ann Hematol"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/10428190500178399","article-title":"Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab.","volume":"46","author":"Woehrer","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R21-11-20210131","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1080\/10428190701509814","article-title":"Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab.","volume":"48","author":"Scaramucci","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R22-11-20210131","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1349-7006.2008.01005.x","article-title":"Histologic and immunophenotypic changes in 59 cases of B-cell non-Hodgkins lymphoma after rituximab therapy.","volume":"100","author":"Maeshima","year":"2009","journal-title":"Cancer Sci"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.pas.0000169496.04283.b9","article-title":"CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkins lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.","volume":"29","author":"Pijuan","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1182\/blood-2003-12-4384","article-title":"Apparent modulation of CD20 by rituximab: an alternative explanation.","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.0303-6987.2005.00305.x","article-title":"The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.","volume":"32","author":"Rawal","year":"2005","journal-title":"J Cutan Pathol"},{"key":"R26-11-20210131","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk Res"},{"key":"R27-11-20210131","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1532\/IJH97.07028","article-title":"Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.","volume":"86","author":"Tomita","year":"2007","journal-title":"Int J Hematol"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"key":"R30-11-20210131","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/j.1349-7006.2012.02307.x","article-title":"Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.","volume":"103","author":"Miyoshi","year":"2012","journal-title":"Cancer Sci"},{"key":"R31-11-20210131","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0b013e3182759008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:57:49Z","timestamp":1620968269000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201304000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0b013e3182759008","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}